Measurement of serum amyloid a4 (SAA4): Its constitutive presence in serum

Toshiyuki Yamada, Barbara Kluve-Beckerman, William M. Kuster, Juris J. Liepnieks, Merrill D. Benson

Research output: Contribution to journalArticle

21 Scopus citations


Newly described human serum amyloid A4 (SAA4) was measured in serum by an enzyme-linked immunosorbent assay using anti-SAA4 monoclonal antibody and recombinant human SAA4 as the assay standard. Interference by elevated acute phase SAA (aSAA) was abolished by the addition of rabbit anti-human aSAA antiserum prior to the addition ofanti-SAA4 to the test samples. Normal levels of SAA4 ranged between 80-140 mg/L, substantially higher than those ofaSAA. No statistically significant difference in SAA4 levels between normal subjects and patients with Mycoplasma pneumonia was seen, indicating that SAA4 does not behave as an acute phase reactant. Low SAA4 levels were found in some patients with high aSAA, although no significant relationship between SAA4 and aSAA was apparent. The constitutive presence of SAA4 in serum suggests a physiologic function different from that ofaSAA.

Original languageEnglish (US)
Pages (from-to)114-118
Number of pages5
Issue number2
StatePublished - Jan 1 1994


  • Acute phase reactant
  • Enzyme-unked immunosorbent assay
  • Recombinant Protein
  • Serum amyloid A

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Measurement of serum amyloid a4 (SAA<sub>4</sub>): Its constitutive presence in serum'. Together they form a unique fingerprint.

  • Cite this